BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KLN-1010 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of KLN-1010\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07075185-3332@assetmemo.bio
DTSTAMP:20261121T005818Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:KLN-1010: Phase 1 readout est. (NCT07075185)
DESCRIPTION:KLN-1010\, phase 1\, Multiple Myeloma.\nStudy: A Study to Evalu
 ate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple
  Myeloma\nEstimated primary completion: March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/kln-1010#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07075185
URL:https://assetmemo.bio/drug/kln-1010#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
